Dyspepsia Epidemiology Forecast

DelveInsight's 'Dyspepsia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Dyspepsia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Dyspepsia Understanding

The DelveInsight Dyspepsia epidemiology report gives a thorough understanding of the Dyspepsia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Dyspepsia in the US, Europe, and Japan. The report covers the detailed information of the Dyspepsia epidemiology scenario in seven major countries (US, EU5, and Japan).


Dyspepsia Epidemiology Perspective by DelveInsight

The Dyspepsia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Dyspepsia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Dyspepsia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Dyspepsia Detailed Epidemiology Segmentation

The Dyspepsia epidemiology covered in the report provides historical as well as forecasted Dyspepsia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Dyspepsia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Dyspepsia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Dyspepsia Epidemiology Report and Model provide an overview of the risk factors and global trends of Dyspepsia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Dyspepsia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Dyspepsia
  • The report provides the segmentation of the Dyspepsia epidemiology


Report Highlights

  • 11-Year Forecast of Dyspepsia epidemiology
  • 7MM Coverage
  • Total Cases of Dyspepsia
  • Total Cases of Dyspepsia according to segmentation
  • Diagnosed cases of Dyspepsia


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dyspepsia?
  • What are the key findings pertaining to the Dyspepsia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Dyspepsia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Dyspepsia?
  • What are the currently available treatments of Dyspepsia?


Reasons to buy

  • The Dyspepsia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Dyspepsia market
  • Quantify patient populations in the global Dyspepsia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Dyspepsia therapeutics in each of the markets covered
  • Understand the magnitude of Dyspepsia population by its epidemiology
  • The Dyspepsia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Dyspepsia

3. Dyspepsia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Dyspepsia Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Dyspepsia Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Dyspepsia Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Dyspepsia Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Dyspepsia Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Dyspepsia Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Dyspepsia Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Dyspepsia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Dyspepsia Treatment and Management

6.2. Dyspepsia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Dyspepsia Epidemiology in 7MM (2017-2030)

Table 2 Dyspepsia Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Dyspepsia Epidemiology in the United States (2017-2030)

Table 4 Dyspepsia Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Dyspepsia Epidemiology in Germany (2017-2030)

Table 6 Dyspepsia Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Dyspepsia Epidemiology in France (2017-2030)

Table 8 Dyspepsia Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Dyspepsia Epidemiology in Italy (2017-2030)

Table 10 Dyspepsia Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Dyspepsia Epidemiology in Spain (2017-2030)

Table 12 Dyspepsia Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Dyspepsia Epidemiology in the United Kingdom (2017-2030)

Table 14 Dyspepsia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Dyspepsia Epidemiology in Japan (2017-2030)

Table 16 Dyspepsia Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Dyspepsia Epidemiology in 7MM (2017-2030)

Figure 2 Dyspepsia Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Dyspepsia Epidemiology in the United States (2017-2030)

Figure 4 Dyspepsia Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Dyspepsia Epidemiology in Germany (2017-2030)

Figure 6 Dyspepsia Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Dyspepsia Epidemiology in France (2017-2030)

Figure 8 Dyspepsia Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Dyspepsia Epidemiology in Italy (2017-2030)

Figure 10 Dyspepsia Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Dyspepsia Epidemiology in Spain (2017-2030)

Figure 12 Dyspepsia Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Dyspepsia Epidemiology in the United Kingdom (2017-2030)

Figure 14 Dyspepsia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Dyspepsia Epidemiology in Japan (2017-2030)

Figure 16 Dyspepsia Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Dyspepsia Epidemiology
  • Dyspepsia
  • Dyspepsia Pipeline
  • Dyspepsia Companies
  • Dyspepsia prevalent population
  • Dyspepsia incident population
  • Dyspepsia patients diagnosed
  • Dyspepsia treatment algorithm

Forward to Friend

Need A Quote